174 related articles for article (PubMed ID: 29567096)
1. Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Cattaneo D; Gianelli U; Bianchi P; Cortelezzi A; Iurlo A
Eur J Intern Med; 2018 Jun; 52():e25-e26. PubMed ID: 29567096
[No Abstract] [Full Text] [Related]
2. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis.
How J; Trinkaus KM; Oh ST
Br J Haematol; 2018 Oct; 183(2):310-313. PubMed ID: 29048104
[No Abstract] [Full Text] [Related]
4. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases.
Lavu S; Szuber N; Mudireddy M; Yogarajah M; Gangat N; Pardanani A; Hanson CA; Ketterling RP; Ashrani AA; Kamath PS; Tefferi A
Am J Hematol; 2018 Mar; 93(3):E61-E64. PubMed ID: 29194707
[No Abstract] [Full Text] [Related]
5. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
6. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
7. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
8. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
9. [Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis].
Campos-Cabrera G; Campos-Cabrera V; Campos-Cabrera S; Campos-Villagómez JL; Romero-González A
Gac Med Mex; 2017; 153(4):537-540. PubMed ID: 28991281
[TBL] [Abstract][Full Text] [Related]
10. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
Kanellopoulou T; Alexopoulou A; Koskinas J
Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
[No Abstract] [Full Text] [Related]
11. CALR exon 9 mutations in idiopathic splanchnic vein thrombosis in an Australian cohort.
Ho WK; Hong FS
Thromb Res; 2017 Feb; 150():51-52. PubMed ID: 28024182
[No Abstract] [Full Text] [Related]
12. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
13. Calreticulin mutations and their importance in splanchnic vein thrombosis.
Sekhar M; Patch D; Austen B; Howard J; Hart S
Br J Haematol; 2016 Jul; 174(1):158-60. PubMed ID: 26358155
[No Abstract] [Full Text] [Related]
14. Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M; McVinnie K; Burroughs AK
Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
[TBL] [Abstract][Full Text] [Related]
15. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
16. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative Neoplasms.
Spivak JL
N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
[No Abstract] [Full Text] [Related]
18. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
19. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
Qi X; Hu F; Yang Z; Han G; Fan D
Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
[No Abstract] [Full Text] [Related]
20. To screen for CALR mutations in patients with splanchnic vein thrombosis?
Haslam K; Langabeer SE
Clin Lab; 2015; 61(3-4):441-2. PubMed ID: 25975015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
